Xbrane Biopharma Correlations
| XBRANE Stock | SEK 0.18 0.01 5.26% |
The current 90-days correlation between Xbrane Biopharma and Hansa Biopharma AB is 0.09 (i.e., Significant diversification). The correlation of Xbrane Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Xbrane Biopharma Correlation With Market
Good diversification
The correlation between Xbrane Biopharma AB and DJI is -0.07 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Xbrane Biopharma AB and DJI in the same portfolio, assuming nothing else is changed.
Xbrane |
The ability to find closely correlated positions to Xbrane Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xbrane Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xbrane Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xbrane Biopharma AB to buy it.
Moving together with Xbrane Stock
| 0.75 | SPRINT | Sprint Bioscience | PairCorr |
| 0.77 | ERIC-A | Telefonaktiebolaget | PairCorr |
| 0.63 | 8TRA | Traton SE | PairCorr |
| 0.77 | VOLV-B | AB Volvo | PairCorr |
| 0.74 | VOLV-A | AB Volvo | PairCorr |
| 0.78 | TRUE-B | Truecaller AB | PairCorr |
Moving against Xbrane Stock
| 0.72 | BIOG-B | BioGaia AB | PairCorr |
| 0.72 | ORX | Orexo AB | PairCorr |
| 0.55 | ERMA | Enorama Pharma AB | PairCorr |
| 0.5 | ELUX-A | AB Electrolux | PairCorr |
| 0.45 | ALZCUR | AlzeCure Pharma | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Risk-Adjusted Indicators
There is a big difference between Xbrane Stock performing well and Xbrane Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Xbrane Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| HNSA | 2.40 | (0.74) | 0.00 | (5.09) | 0.00 | 3.40 | 21.12 | |||
| VICO | 2.68 | (0.94) | 0.00 | (0.72) | 0.00 | 3.39 | 52.59 | |||
| XSPRAY | 2.23 | (0.15) | 0.00 | 0.26 | 0.00 | 5.26 | 25.50 | |||
| SANION | 3.90 | 0.29 | 0.00 | 0.03 | 0.00 | 5.57 | 72.42 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Xbrane Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Companies Directory Now
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
| All Next | Launch Module |
Xbrane Biopharma Corporate Management
Elected by the shareholders, the Xbrane Biopharma's board of directors comprises two types of representatives: Xbrane Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xbrane. The board's role is to monitor Xbrane Biopharma's management team and ensure that shareholders' interests are well served. Xbrane Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xbrane Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nina Ivers | Head HR | Profile | |
| Maria Edebrink | Head Assurance | Profile | |
| Dina Jurman | Head of Clinical Affairs | Profile | |
| Anette Lindqvist | CFO Relations | Profile | |
| Martin mark | Chief Officer | Profile | |
| David Vikstrm | Chief Officer | Profile |